Cargando…
Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
BACKGROUND: Prostate cancer (PCa) is one of the most diagnosed cancers in the world. PCa inevitably progresses to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment, and castration-resistant state means a shorter survival time than other causes. Here we aimed to...
Autores principales: | Li, Yan, Shi, Hui, Zhao, Zhenjun, Xu, Minghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580185/ https://www.ncbi.nlm.nih.gov/pubmed/36258196 http://dx.doi.org/10.1186/s12894-022-01113-5 |
Ejemplares similares
-
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015) -
Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC)
por: Humphreys, Michael R, et al.
Publicado: (2013) -
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014) -
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021) -
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Gamat-Huber, Melissa, et al.
Publicado: (2020)